Background Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with
few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor …

Chinese translation Background: Hidradenitis suppurativa (HS) is a chronic, painful skin
disease characterized by abscesses, nodules, and draining fistulas in the axilla and groin of …

Objective To evaluate the safety and efficacy of adalimumab for the management of
hidradenitis suppurativa (HS). Methods In a prospective open‐label phase II study …

BACKGROUND: Medical therapies for hidradenitis suppurativa (HS) are often ineffective.
Tumor necrosis factor-α inhibitors may be a potential treatment for patients with moderate to …

Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized
by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various …

Background Hidradenitis suppurativa (HS) is a difficult‐to‐manage disease. Randomized
controlled trials with antitumour necrosis factor (TNF)‐α biologics have been conducted and …

Background: Greater understanding of the roles of tumor necrosis factor-α, IL-1β, IL-10, and
the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways in immune dysregulation in …

Background Several studies report the use of tumor necrosis factor α (TNF-α) inhibitors in
refractory hidradenitis suppurativa (HS), particularly infliximab and etanercept. However …

Background Hidradenitis suppurativa (HS) has an impact on patients' quality of life.
Treatment of HS is generally unsatisfactory, thus new treatments are needed. Objectives To …

Background Hidradenitis suppurativa (HS) is a chronic debilitating autoinflammatory skin
disease. Adalimumab is the only biologic agent available to treat HS, but lack of response is …